Take a behind-the-scenes look at how researchers study lung cancer. Join lung cancer researcher Triparna Sen, PhD, as she digs into what’s known about how EGFR-positive NSCLC cells transform into SCLC to escape targeted therapy treatment. SCLC transformation is a common resistance mechanism for multiple types of NSCLC, including EGFR, ALK, and RET.
This Facebook Live event is hosted by Amy Moore, PhD, LUNGevity’s Vice President of Global Engagements and Patient Partnerships. Dr. Sen is Co-Director of the Lung Cancer PDX Platform at the Center for Thoracic Oncology, Icahn School of Medicine at Mount Sinai, New York.